secretagogue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。
Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。
在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
| Property | Value | Notes |
|---|---|---|
| 分子式 | C38H49N9O5 | 五肽，含非天然氨基酸残基 |
| 分子量 | 711.85 g/mol | 理论值，盐形式可能略有差异 |
| 外观 | 白色至类白色粉末 | 冻干粉常见 |
| 溶解性 | 易溶于水 | 也可溶于部分极性有机溶剂 |
| 储存条件 | -20°C，干燥避光 | 长期保存通常推荐 |
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Congenital opacities may occur as developmental anomalies or following birth trauma. Causes of congenital corneal opacities include sclerocornea, trauma, ulcer, mucopolysaccharidosis, Peter's anomaly, congenital hereditary endothelial dystrophy. Ocular trauma Corneal ulceration Xerophthalmia, caused by Vitamin A deficiency Trachoma Onchocerciasis Mucous membrane pemphigoid: Ocular form of mucous membrane pemphigoid may cause corneal opacity and loss of vision. Death
It has been indicated that where there was a policy of providing IAP for GBS colonized mothers, the overall risk of EOGBS is 0.3%. Though maternal GBS colonization is the key determinant for EOD, other factors also increase the risk. These factors include onset of labor before 37 weeks of gestation (premature birth), prolonged rupture of membranes (> 18 h before delivery), intra-partum fever (>38 °C, >100.4 °F), amniotic infections (chorioamnionitis), young maternal age, and low levels of GBS anticapsular polysaccharide antibodies in the mother. Nevertheless, most babies who develop EOD are born to GBS colonized mothers without any additional risk factor. A previous sibling with EOD is also an important risk factor for the development of the infection in subsequent deliveries, probably reflecting a lack of GBS polysaccharides protective antibodies in the mother. Heavy GBS vaginal colonization is also associated with a higher risk for EOD. Overall, the case–fatality rates from EOD have declined, from 50% observed in studies from the 1970s to 2 to 10% in recent years, mainly as a consequence of improvements in therapy and management. Fatal neonatal infections by GBS are more frequent among premature infants. GBS LOD affects infants from 7 days to 3 months of age and is more likely to cause bacteremia or meningitis. LOD can be acquired from the mother or from environmental sources. Hearing loss and mental impairment can be long-term sequelae of GBS meningitis.
==== Umeko ==== Koume Kodou (胡堂 小梅, Kodō Koume), also known as "Umeko" (ウメコ), is a ditzy, yet kind-hearted and perky, member of the team who serves as Deka Pink (デカピンク, Deka Pinku), though she frequently claims to be the field leader. Throughout the series, she spends every moment she can in a bubble bath with her three rubber ducks, Umeyo, Umenosuke, and Umegoro. After learning of Sen-chan's feelings for her, she moves in with him, as of the crossover film Mahō Sentai Magiranger vs. Dekaranger. As Deka Pink, Umeko wields the D-Knuckle and D-Stick, which can combine to form the D-Shot and allow her to perform the Twin Cam Shot alongside Jasmine. Using the SP License's Masquerade Mode (マスカレイドモード, Masukareido Mōdo), she can instantaneously change her outfit for disguise purposes. Umeko is portrayed by Mika Kikuchi (菊地 美香, Kikuchi Mika).
== Development history == Bimagrumab was developed by Novartis, in collaboration with Morphosys. On August 20, 2013, it was announced that bimagrumab had received a breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by the US Food and Drug Administration (FDA). In 2014, Bimagrumab entered Phase II development, with some research indicating clinical effects. Novartis planned to apply in 2016 for FDA approval to treat sIBM patients with bimagrumab. In April 2016, Novartis announced that bimagrumab had failed a Phase IIb/III study for sporadic inclusion body myositis. In January 2021, a new study confirmed that treatment with bimagrumab is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes. Novartis then licensed the drug to Versanis Bio, a Medicxi Fund and Atlas Venture-backed startup, who closed a series A financing round to fund a phase II clinical program targeting weight loss in obese patients. In January 2023 Versanis Bio entered the medication into phase IIb trials for obesity. In July 2023, Eli Lilly bought Versanis Bio for their weight loss asset for $1.9 billion. In 2025, a phase IIb study was concluded testing bimagrumab in combination with Novo Nordisk's semaglutide, demonstrating that the combination resulted in a greater loss of fat as a percentage of weight compared to semaglutide alone. In September 2025, Eli Lilly terminated a phase IIb study investigating a tirzepatide-bimagrumab combination in obese and type II diabetic patients.
Sources: en.wikipedia.org
=== Conformation change mechanism pathway (without proteolysis) === αVβ6 integrin was the first integrin to be identified as TGF-β1 activator. LAPs contain an RGD motif which is recognized by vast majority of αV containing integrins, and αVβ6 integrin can activate TGF-β1 by binding to the RGD motif present in LAP-β1 and LAP-β3. Upon binding, it induces adhesion-mediated cell forces that are translated into biochemical signals which can lead to liberation/activation of TGFb from its latent complex. This pathway has been demonstrated for activation of TGF-β in epithelial cells and does not associate MMPs.
== Monetary policy committee == The Reserve Bank of India Act, 1934 (RBI Act) was amended by the Finance Act, 2016, to provide a statutory and institutionalised framework for a Monetary Policy Committee, for maintaining price stability, while keeping in mind the objective of growth. The Monetary Policy Committee is entrusted with the task of fixing the benchmark policy rate (repo rate) required to maintain inflation within the specified target level. As per the provisions of the RBI Act, three of the six Members of the Monetary Policy Committee will be from the RBI and the other three Members will be appointed by the Central Government. The Government of India, in consultation with RBI, notified the 'Inflation Target' in the Gazette of India Extraordinary dated 5 August 2016 for the period beginning from the date of publication of the notification and ending on 31 March 2021 as 4%. At the same time, lower and upper tolerance levels were notified to be 2% and 6% respectively. Inflation rate in 2020 is 6.2% .
Lead, antimony, and barium Barium, calcium, and silicon Antimony Barium The authors proposed some rules about chemical elements that could also be present in these particles. Wallace and McQuillan published a new classification of the gunshot residue particles in 1984. They labeled as unique particles those that contain lead, antimony, and barium, or that contain antimony and barium. Wallace and McQuillan also maintained that these particles could contain only some chemical elements.
=== Diet === For most horses, diet has a significant impact on the degree of clinical signs. PSSM horses fed diets high in nonstructural carbohydrates (NSC), which stimulate insulin secretion, have been shown to have increased severity of rhabdomyolysis with exercise. Current recommendations for horses with PSSM include a low-starch, high-fat diet. Low-starch diets produce low blood glucose and insulin levels after eating, which may reduce the amount of glucose taken up by the muscle cells. High fat diets increase free fatty acid concentrations in the blood, which may promote the use of fat for energy (via free fatty acid oxidation) over glucose metabolism. Horses with the most severe clinical signs often show the greatest improvement on the diet. Dietary recommendations usually include a combination of calorie restriction, reduction of daily NSC content, and an increase in dietary fat. Diet recommendations need to be balanced with the animal's body condition score and exercise level, as it may be beneficial to wait on increasing dietary fat after an obese animal has lost weight. The diet should have <10% of digestible energy coming from NSC, and 15–20% of daily digestible energy coming from fat.
In AMS v Union locale des syndicats CGT a French trade union claimed that the French Labour Code should not exclude casual workers from counting toward the right to set up a work council that an employing entity must inform and consult. They said this contravened the Information and Consultation of Employees Directive and also CFREU article 27. The Court of Justice agreed that the French Labour Code was incompatible with the Directive, but held that article 27 was expressed too generally to create direct rights. On this view, legislation was necessary to make abstract human rights principles concrete, and legally enforceable. Beyond human rights, the Court of Justice has recognised at least five further 'general principles' of EU law. The categories of general principles are not closed, and may develop according to the social expectations of people living in Europe.
Sources: en.wikipedia.org
不是。它属于人工合成的五肽，设计上模拟胃饥饿素受体的部分作用，但不存在于人体天然激素谱中。
生长激素释放激素通过其专用受体起作用，而 ipamorelin 主要作用于胃饥饿素受体。两者可影响生长激素释放，但信号通路和下游效应并不相同。
研究多集中在生长激素释放的急性调节、受体选择性以及不同给药方式下的药代动力学。临床终点研究数量有限，长期结局尚不明确。
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.